Log inSign up
AAOIFI No. 21 screening

Is RDHL halal?

Redhill Biopharma Ltd.

Not halal

Redhill Biopharma Ltd. did not pass AAOIFI screening. The failed check is shown below.

Checked: 14 October 2026

Exchange

NASDAQ

Price

0.4801

Day

-3.81%

Market cap

$4.4M

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

What the company does

RedHill Biopharma (Israel) is a specialty pharma that sells Talicia (H. pylori infection) and previously Movantik; revenue is now small while it develops opaganib (antiviral/oncology) and other candidates. It exited heavy debt and has reverse-split many times.

What was checked

The AAOIFI standard has four steps: business activity first, then three financial ratios. Fail one and the stock is not halal.

  • Business activity

    No prohibited activity

  • Interest-bearing debt / market cap

    limit 30%

    Interest-bearing debt $1.07M ÷ current market cap $4.42M = 24.2%

    24.2%

    Pass

  • Cash & investments / market cap

    limit 30%

    Cash + interest-bearing securities $3.97M ÷ current market cap $4.42M = 89.8%

    89.8%

    Fail

  • Non-compliant income / total revenue

    limit 5%

    Interest income $23K ÷ annual revenue $286K (2025) = 8.0%

    8.0%

    Fail

Figures from the company's filings (2025-12-31), USD. Market cap is a 36-month average (the S&P Shariah index approach), so a one-day price move does not flip the verdict.

For information (AAOIFI 3/1 note): cash + receivables are 25.4% of total assets (2025-12-31). AAOIFI recommends tangible assets of at least one third — this figure does not affect the verdict, and other major screeners do not apply it either.

In the lists

In the S&P 500
Not in the S&P 500

Halal stocks in the same industry

The largest halal stocks in Drug Manufacturers - Specialty & Generic — for comparison.

Related articles

Halal is the first question. The second: when to enter?

Our scanner watches 1454 halal stocks around the clock and fires a signal with entry, TP and SL when a technical setup completes. The full signal history — with outcomes — is public.

This is neither investment advice nor a fatwa. Screening is based on public financial statements and AAOIFI standard No. 21; data may lag. For a personal decision consult your own scholar.